Literature DB >> 16184611

Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.

Akira Kurose1, Toshiki Tanaka, Xuan Huang, H Dorota Halicka, Frank Traganos, Wei Dai, Zbigniew Darzynkiewicz.   

Abstract

BACKGROUND: The ATM kinase regulates cell-cycle checkpoints by phosphorylating multiple proteins, including histone H2AX, CHK1, and CHK2 kinases and p53. ATM is activated through auto- or trans- phosphorylation of Ser-1981 in response to DNA damage, particularly induction of DNA double-strand breaks (DSBs). The aim of the present study was to reveal a possible correlation between activation of ATM vis-à-vis H2AX phosphorylation, cell cycle phase, and apoptosis in cells treated with DNA topoisomerase (topo) I (topotecan; Tpt) or topo2 (mitoxantrone; Mtx) inhibitor.
MATERIALS AND METHODS: Cultures of HL-60 cells were treated with Tpt or Mtx for various time intervals. ATM or H2AX phosphorylation was detected immunocytochemically, using Ab specific for ATM phosphorylated on Ser-1981 (ATM-S1981(P)) or for H2AX (gammaH2AX) phosphorylated on Ser-139, respectively, concurrent with the analysis of cellular DNA content. Cellular fluorescence was measured by flow cytometry.
RESULTS: Untreated cells showed a modest but variable level of labeling with ATM-S1981(P) Ab across the cell cycle, with exception of mitotic cells that were strongly labeled. Exposure of cells to 150 nM Tpt induced ATM phosphorylation concurrent with phosphorylation of H2AX within 10 min; phosphorylation of both proteins was essentially limited to S-phase and was suppressed by caffeine and wortmannin, inhibitors of PI-3-like kinases. Exposure of cells to Mtx also led to ATM and H2AX phosphorylation, which, compared to Tpt, occurred later and was not cell-cycle-phase specific. Apoptosis of HL-60 cells in Tpt or Mtx treated cultures was detected after 2 or 4 h, respectively, and was limited to S-phase cells.
CONCLUSIONS: The data are consistent with the role of ATM as a mediator of H2AX phosphorylation in response to DNA damage by topo1 (Tpt) or topo 2 (Mtx) inhibitor. The observed cell-cycle-phase related differences in response to Tpt vs Mtx suggest that while the collisions of DNA replication forks with the "cleavable complexes" stabilized by topo1 inhibitor are the primary cause of DSBs induced by Tpt, the collisions of RNA polymerase molecules with the complexes stabilized by the topo2 inhibitor play a major role for induction of DSBs by Mtx. The present report is the first that (i) describes cytometric analysis of ATM activation and (ii) demonstrates activation of the enzyme (kinase) and its consequence (substrate phoshorylation), both in relation to cell-cycle phase and onset of apoptosis within the same cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184611     DOI: 10.1002/cyto.a.20186

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  37 in total

1.  Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Authors:  Robert J Kinders; Melinda Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.

Authors:  Hong Zhao; Paulina Rybak; Jurek Dobrucki; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2011-12-02       Impact factor: 4.355

3.  Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Authors:  Drew D Dudgeon; Sunita N Shinde; Tong Ying Shun; John S Lazo; Christopher J Strock; Kenneth A Giuliano; D Lansing Taylor; Patricia A Johnston; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2010-08       Impact factor: 1.738

4.  DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.

Authors:  Maki Ikeda; Akira Kurose; Eriko Takatori; Toru Sugiyama; Frank Traganos; Zbigniew Darzynkiewicz; Takashi Sawai
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

5.  Sulfur Mustard Analog Mechlorethamine (Bis(2-chloroethyl)methylamine) Modulates Cell Cycle Progression via the DNA Damage Response in Human Lung Epithelial A549 Cells.

Authors:  Yi-Hua Jan; Diane E Heck; Debra L Laskin; Jeffrey D Laskin
Journal:  Chem Res Toxicol       Date:  2019-04-22       Impact factor: 3.739

6.  Cell synchronization by inhibitors of DNA replication induces replication stress and DNA damage response: analysis by flow cytometry.

Authors:  Zbigniew Darzynkiewicz; H Dorota Halicka; Hong Zhao; Monika Podhorecka
Journal:  Methods Mol Biol       Date:  2011

Review 7.  Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents.

Authors:  Toshiki Tanaka; Xuan Huang; H Dorota Halicka; Hong Zhao; Frank Traganos; Anthony P Albino; Wei Dai; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2007-09       Impact factor: 4.355

8.  Mechanisms of leukemia translocations.

Authors:  Jac A Nickoloff; Leyma P De Haro; Justin Wray; Robert Hromas
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

9.  Extent of constitutive histone H2AX phosphorylation on Ser-139 varies in cells with different TP53 status.

Authors:  T Tanaka; A Kurose; X Huang; F Traganos; W Dai; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

10.  Kinetics of the UV-induced DNA damage response in relation to cell cycle phase. Correlation with DNA replication.

Authors:  Hong Zhao; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2010-03       Impact factor: 4.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.